Skip to main content


U.S. flag
      An official website of the United States government
              Here’s how you know
        Here’s how you knowDot gov**Official websites use .gov**
                 A **.gov** website belongs to an official government organization in the United States.
                  HTTPS**Secure .gov websites use HTTPS**
                 A **lock** (A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. 
  Menu Close
          HHS Search block
    Search
        








  
  
    

  
      

                                      About HHS
    
                        
                              
      
      
      Programs & Services
    
                        
                              
      
      
      Grants & Contracts
    
                        
                              
      
      
      Laws & Regulations Breadcrumb
    Home
                              About
                              News
                              Secretary Becerra Announces HHS Purchase of 600,000 Treatment Courses of New Monoclonal Antibody That Works Against Omicron
 Navigate to:
  News
    
                                    
                                            
            
      
      
      
      Blog
    
                                    
                                            
            
      
      
      
      HHS Live
    
                                    
                                            
            
      
      
      
      Podcasts
    
                                    
                                            
            
      
      
      
      Media Guidelines for HHS EmployeesText resize icon

                    




**FOR IMMEDIATE RELEASE February 10, 2022**

        **Contact: 
                                    HHS Press Office**
          202-690-6343media@hhs.gov

          Secretary Becerra Announces HHS Purchase of 600,000 Treatment Courses of New Monoclonal Antibody That Works Against Omicron
    
    

      *If It Receives EUA, This New Treatment by Lilly Would Be Provided to States Free of Charge and Add Another COVID-19 Treatment to Nation’s Medicine Cabinet*

*Purchase Demonstrates Biden-Harris Administration’s Preparedness for Future Needs Treating COVID-19, Reducing Severe Disease, and Protecting Americans*

As part of the Biden-Harris Administration’s commitment to ensuring Americans who get sick with COVID-19 have access to treatments that work, today U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra is announcing that the federal government has purchased 600,000 treatment courses of a new monoclonal antibody treatment that data shows works against the Omicron variant. The new monoclonal antibody treatment, bebtelovimab, is manufactured by Eli Lilly and Company, and if it receives emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA), HHS will make the treatment available to states free of charge.

“Under President Biden’s leadership, we are prepared for the challenges we face with COVID-19 and are laser-focused on saving lives,” said Secretary Becerra. “We have more COVID-19 treatments than ever before, we are providing a billion free at-home tests, and we have enough vaccines to get everyone vaccinated and boosted. If authorized by FDA, this purchase will add an additional 600,000 courses of treatment to our nation’s ‘medicine cabinet’ that could help prevent severe outcomes for Americans who do get sick with COVID-19. Our top priority is preventing people from getting sick in the first place, which is why it is critical that Americans continue to get vaccinated and get their booster shot as soon as they’re eligible.”

HHS would receive approximately 300,000 treatment courses of this monoclonal antibody in February and approximately 300,000 treatment courses in March. Recently, it was determined that data shows that two monoclonal antibody treatments – one made by Lilly (bamlanivimab/etesevimab), and one made by Regeneron (REGEN-COV) – are highly unlikely to work against Omicron, which currently is estimated to make up about 100 percent of all COVID-19 cases in the U.S. Early data suggests that this new product by Lilly has activity against both Omicron and the BA.2 Omicron subvariant. Should the BA.2 subvariant grow in proportion in the U.S., this potential treatment may help ensure that we can continue to offer monoclonal antibody treatment that works against that strain of the virus.

“We want to make sure if an American gets sick with COVID-19, they can get a treatment that works,” added Secretary Becerra.

If it receives EUA, HHS is prepared to immediately make this treatment available. Already this year, HHS has provided more than 2.5 million COVID-19 treatments and therapies to states for Americans who get sick with COVID-19 to use, including antiviral pills, monoclonal antibodies, and pre-exposure prophylaxis therapies for people with compromised immune systems.

The contract also includes a future option for 500,000 more doses and was awarded as a result of collaboration between the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
  

    ###
    Note: All HHS press releases, fact sheets and other news materials are available at https://www.hhs.gov/news.Like HHS on Facebook, follow HHS on Twitter @HHSgov, and sign up for HHS Email Updates.Last revised: February 10, 2022

  
  
  







  Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases

Sign Up







  Subscribe to RSS
    

      Receive latest updates







  Related News Releases
    

      COVID-19 Vaccination Public Education Campaign Saved Thousands of Lives, Billions of Dollars
  

HHS, DHS, and FEMA Announce Completion of Multi-Year Review of State Efforts to Provide Language Access During the COVID-19 Public Health Emergency
  

Readout of HHS Secretary Becerra’s Meeting with Pharmacy CEOs on COVID-19 Therapeutics Commercialization







  Related Blog Posts
    

      Calling innovators! HHS Long COVID Healthathon launches with $25K in prizes
  

Reflections from the Deputy Director of the HHS Office of Long COVID Research and Practice
  

Driving Long COVID Innovation with Health+ Human-Centered Design

                    
  


Media Inquiries

For general media inquiries, please contact media@hhs.gov.







  Content created by Assistant Secretary for Public Affairs (ASPA) Content last reviewed February 10, 2022 Back to top
    Contact HHS
    
                        
                                            
      
      
      Careers
    
                        
                                            
      
      
      HHS FAQs
    
                        
                                            
      
      
      Nondiscrimination NoticeHHS Archive
    
                        
                                            
      
      
      Accessibility Statement
    
                        
                                            
      
      
      Privacy Policy
    
                        
                                            
      
      
      Viewers & PlayersBudget/Performance
    
                        
                                            
      
      
      Inspector General
    
                        
                                            
      
      
      Web Site Disclaimers
    
                        
                                            
      
      
      EEO/No Fear ActFOIA
    
                        
                                            
      
      
      The White House
    
                        
                                            
      
      
      USA.gov
    
                        
                                            
      
      
      Vulnerability Disclosure Policy
        Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
  HHS Headquarters
          200 Independence Avenue, S.W.
                  Washington, D.C. 20201
                  Toll Free Call Center: 1-877-696-6775​ Disclaimer Policy: Links with this icon () mean that you are leaving the HHS website. The Department of Health and Human Services (HHS) cannot guarantee the accuracy of a non-federal website.
                  Linking to a non-federal website does not mean that HHS or its employees endorse the sponsors, information, or products presented on the website. HHS links outside of itself to provide you with further information.
                  You will be bound by the destination website's privacy policy and/or terms of service when you follow the link.
                  HHS is not responsible for Section 508 compliance (accessibility) on private websites. For more information on HHS's web notification policies, see Website Disclaimers.
 Continue
                  Go back